|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ST3GAL6 |
Gene summary for ST3GAL6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ST3GAL6 | Gene ID | 10402 |
| Gene name | ST3 beta-galactoside alpha-2,3-sialyltransferase 6 | |
| Gene Alias | SIAT10 | |
| Cytomap | 3q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | A0A087WXB8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10402 | ST3GAL6 | NAFLD1 | Human | Liver | NAFLD | 7.03e-14 | 1.31e+00 | -0.04 |
| 10402 | ST3GAL6 | HCC1_Meng | Human | Liver | HCC | 4.93e-45 | -4.65e-02 | 0.0246 |
| 10402 | ST3GAL6 | HCC2_Meng | Human | Liver | HCC | 5.64e-06 | -1.21e-01 | 0.0107 |
| 10402 | ST3GAL6 | cirrhotic1 | Human | Liver | Cirrhotic | 6.06e-03 | -1.75e-01 | 0.0202 |
| 10402 | ST3GAL6 | cirrhotic2 | Human | Liver | Cirrhotic | 1.33e-03 | -1.70e-01 | 0.0201 |
| 10402 | ST3GAL6 | cirrhotic3 | Human | Liver | Cirrhotic | 4.11e-02 | -1.88e-01 | 0.0215 |
| 10402 | ST3GAL6 | HCC1 | Human | Liver | HCC | 3.69e-02 | 1.69e+00 | 0.5336 |
| 10402 | ST3GAL6 | HCC2 | Human | Liver | HCC | 5.85e-04 | 1.93e+00 | 0.5341 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016051 | Liver | NAFLD | carbohydrate biosynthetic process | 43/1882 | 202/18723 | 1.55e-06 | 6.96e-05 | 43 |
| GO:00067904 | Liver | NAFLD | sulfur compound metabolic process | 58/1882 | 339/18723 | 3.79e-05 | 9.38e-04 | 58 |
| GO:0044272 | Liver | NAFLD | sulfur compound biosynthetic process | 28/1882 | 148/18723 | 7.52e-04 | 9.52e-03 | 28 |
| GO:0070741 | Liver | NAFLD | response to interleukin-6 | 12/1882 | 49/18723 | 2.77e-03 | 2.53e-02 | 12 |
| GO:0071354 | Liver | NAFLD | cellular response to interleukin-6 | 11/1882 | 45/18723 | 4.16e-03 | 3.47e-02 | 11 |
| GO:000679011 | Liver | Cirrhotic | sulfur compound metabolic process | 129/4634 | 339/18723 | 3.06e-08 | 1.04e-06 | 129 |
| GO:00442721 | Liver | Cirrhotic | sulfur compound biosynthetic process | 58/4634 | 148/18723 | 6.93e-05 | 7.83e-04 | 58 |
| GO:00160511 | Liver | Cirrhotic | carbohydrate biosynthetic process | 73/4634 | 202/18723 | 1.91e-04 | 1.77e-03 | 73 |
| GO:0006643 | Liver | Cirrhotic | membrane lipid metabolic process | 69/4634 | 203/18723 | 1.89e-03 | 1.19e-02 | 69 |
| GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
| GO:00442722 | Liver | HCC | sulfur compound biosynthetic process | 95/7958 | 148/18723 | 7.89e-08 | 1.58e-06 | 95 |
| GO:00066431 | Liver | HCC | membrane lipid metabolic process | 115/7958 | 203/18723 | 3.17e-05 | 3.22e-04 | 115 |
| GO:00160512 | Liver | HCC | carbohydrate biosynthetic process | 113/7958 | 202/18723 | 7.64e-05 | 6.83e-04 | 113 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:0006664 | Liver | HCC | glycolipid metabolic process | 57/7958 | 100/18723 | 2.40e-03 | 1.17e-02 | 57 |
| GO:1903509 | Liver | HCC | liposaccharide metabolic process | 57/7958 | 101/18723 | 3.25e-03 | 1.49e-02 | 57 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ST3GAL6 | SNV | Missense_Mutation | novel | c.327N>T | p.Arg109Ser | p.R109S | protein_coding | tolerated(0.08) | possibly_damaging(0.757) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR | |
| ST3GAL6 | SNV | Missense_Mutation | novel | c.976N>A | p.Glu326Lys | p.E326K | protein_coding | deleterious(0.05) | probably_damaging(0.999) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ST3GAL6 | insertion | Nonsense_Mutation | novel | c.580_581insGATAGCCTCAACAACTTTCCCTTCTGTGGTTTTGTTCCC | p.Val194delinsGlyTerProGlnGlnLeuSerLeuLeuTrpPheCysSerLeu | p.V194delinsG*PQQLSLLWFCSL | protein_coding | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| ST3GAL6 | SNV | Missense_Mutation | novel | c.1075T>C | p.Tyr359His | p.Y359H | protein_coding | tolerated(0.08) | probably_damaging(0.97) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ST3GAL6 | SNV | Missense_Mutation | novel | c.736N>T | p.Asp246Tyr | p.D246Y | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A3HD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| ST3GAL6 | SNV | Missense_Mutation | c.851N>A | p.Pro284His | p.P284H | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| ST3GAL6 | SNV | Missense_Mutation | novel | c.548N>G | p.Lys183Arg | p.K183R | protein_coding | deleterious(0.03) | probably_damaging(0.911) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ST3GAL6 | SNV | Missense_Mutation | c.550N>G | p.Thr184Ala | p.T184A | protein_coding | deleterious(0) | possibly_damaging(0.508) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| ST3GAL6 | SNV | Missense_Mutation | novel | c.543N>T | p.Lys181Asn | p.K181N | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| ST3GAL6 | SNV | Missense_Mutation | c.785N>C | p.Asn262Thr | p.N262T | protein_coding | tolerated(0.12) | benign(0.287) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |